Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
76 hedge funds and large institutions have $219M invested in Progenics Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 20 closing their positions.
21% more call options, than puts
Call options by funds: $948K | Put options by funds: $781K
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
3% more capital invested
Capital invested by funds: $214M → $219M (+$5.53M)
13% less funds holding
Funds holding: 87 → 76 (-11)
55% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$4.01M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$785K |
| 3 |
Millennium Management
New York
|
+$505K |
| 4 |
JG
Jefferies Group
New York
|
+$496K |
| 5 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$482K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCA
Taconic Capital Advisors
New York
|
-$3.21M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.6M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.46M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.26M |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$708K |
PGNX Hedge Fund Activity: Q2 2014 in Review
76 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2014, worth a combined $219M — up 2.6% from $214M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of PGNX and 9 opened new positions — a net loss of 11 holders — while 25 trimmed existing stakes and 28 added.
The largest buyer was Broadfin Capital, adding an estimated $4.01M. The largest seller was Taconic Capital Advisors, exiting entirely with an estimated $3.21M sold.
- 76 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2014, down from 87 in Q1 2014.
- Funds reported $219M of Progenics Pharmaceuticals Inc stock for Q2 2014, up 2.6% quarter-over-quarter.
- 9 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2014 and 20 closed out, a net change of -11 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q2 2014 was Broadfin Capital, an estimated $4.01M added.
- The largest Progenics Pharmaceuticals Inc seller in Q2 2014 was Taconic Capital Advisors, an estimated $3.21M sold.
Based on aggregated 13F filings for Q2 2014.